RESEARCH PROGRESS REPORT SUMMARY

Grant 02309: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma

Principal Investigator: Angela McCleary-Wheeler, DVM, PhD
Research Institution: Cornell University
Grant Amount: $78,069.00
Start Date: 1/1/2017 End Date: 12/31/2019
Progress Report: Mid-Year 2
Report Due: 6/30/2018 Report Received: 6/30/2018

(The content of this report is not confidential and may be used in communications with your organization.)

Original Project Description:

Canine lymphoma is one of the most common cancers in dogs. While some breeds appear more at risk than others, all can be affected. While often treatable, canine lymphoma can rarely be cured. A continued understanding of the mechanisms causing lymphoma in dogs and identification of novel therapies are needed to improve survival in dogs with lymphoma. One area of research that has been actively explored and provided exciting breakthroughs for human lymphoma is epigenetics, or alterations in how genes are turned on and off independent of the DNA sequence. One way in which this occurs is due to modifications of the proteins that interact with DNA called histones. Various modifications to these histones can result in genes being turned on or off, leading to the development of cancer. One particular enzyme that modifies histones, EZH2, has been found to play a role in some human lymphomas. However, this has been unexplored in canine lymphoma. Given the striking similarities between human and canine lymphoma, the objective of this work is to characterize the function and role of EZH2 in canine lymphoma. The investigators will utilize an EZH2 inhibitor to study EZH2 in canine lymphoma cells. The information obtained from this study will help guide the future development of this targeted inhibitor for use as a novel therapy to treat canine lymphoma.

Publications:

Abstract
McCleary-Wheeler, Angela; Markant, Shirley; Richards, Kristy; Melnick, Ari. (2017, October). The Effect of EZH2 Inhibition in Canine Diffuse Large B-Cell Lymphoma. Veterinary Cancer Society Conference 2017, Portland, OR
A manuscript showcasing this work is in preparation as the data is gathered and the aims of the project are achieved. An abstract was prepared for the annual conference of the Veterinary Cancer Society that was held in October 2017 and was published in the conference proceedings.

Presentations:

The work was presented as a poster presentation at the Veterinary Cancer Society Annual Conference in October 2017.

Report to Grant Sponsor from Investigator:

Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Recently, advances in the understanding of human lymphomas have focused on the area of epigenetics. One area of this research involves understanding how genes are turned on or off based on different modifications to histone proteins, a specific group of proteins that interact with DNA. Specific enzymes that modify these histone proteins have altered activity that can lead to lymphoma development in human lymphomas. One of these enzymes is EZH2. Increased activity of EZH2 has been shown to play an important role in the development of some human lymphomas. Very recently, data from a Phase I study of the EZH2 inhibitor, tazemetostat, in relapsed or refractory human B-cell, non-Hodgkin lymphoma has shown safety and potential benefit. The role of EZH2, however, has not been evaluated in canine lymphomas to date. Given the similarity between human and canine B-cell lymphoma, we sought to investigate whether EZH2 activity plays a role in canine B-cell lymphoma. To do this, we use canine lymphoma cells and specific EZH2 inhibitors, including the tazemetostat used in early human studies, to evaluate the effect of EZH2 inhibition on cell growth and survival. Our data suggest that this inhibitor is highly potent and effective for inhibiting EZH2 activity in canine lymphoma cells. This is important as this inhibitor is an orally bioavailable drug with a good toxicity profile in human, making this inhibitor the best candidate for clinical trials in dogs with lymphoma. Initial data suggests that EZH2 inhibition may not impede lymphoma cell proliferation or survival. However, evaluation of the genes EZH2 regulates is needed to understand why this is the case. We have confirmed that some genes that regulate the ability of canine lymphoma cells to replicate are altered with EZH2 inhibition. Specifically, one gene, CDKN1a, is turned back on when EZH2 is inhibited. The activation of CDKN1a is repeatable and profound. We will be continuing this work with a sequencing approach to further understand what genes are regulated by EZH2 in canine B-cell lymphoma. Our findings are suggesting an importance for EZH2 in canine lymphoma and for continued investigations into cell cycle regulators that may be abnormal. We are encouraged by the data thus far and look forward to evaluation of sequencing results. We appreciate the continued generous support provided by this grant from the CHF and its supporting donors.